The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk - PubMed (original) (raw)
. 2015 Dec;24(12):1855-63.
doi: 10.1158/1055-9965.EPI-15-0422. Epub 2015 Sep 24.
Masayoshi Takeuchi 2, Hideyuki Hyogo 3, Gail McKeown-Eyssen 4, Sho-Ichi Yamagishi 5, Kazuaki Chayama 3, Peter J O'Brien 6, Pietro Ferrari 1, Kim Overvad 7, Anja Olsen 8, Anne Tjønneland 8, Marie-Christine Boutron-Ruault 9, Nadia Bastide 9, Franck Carbonnel 10, Tilman Kühn 11, Rudolf Kaaks 11, Heiner Boeing 12, Krasimira Aleksandrova 12, Antonia Trichopoulou 13, Pagona Lagiou 14, Effie Vasilopoulou 15, Giovanna Masala 16, Valeria Pala 17, Maria Santucci De Magistris 18, Rosario Tumino [ 19](#full-view-affiliation-19 "Cancer Registry and Histopathology Unit, "Civic - MP Arezzo" Hospital, Ragusa, Italy."), Alessio Naccarati 20, H B Bueno-de-Mesquita 21, Petra H Peeters 22, Elisabete Weiderpass 23, J Ramón Quirós 24, Paula Jakszyn 25, María-José Sánchez 26, Miren Dorronsoro 27, Diana Gavrila 28, Eva Ardanaz 29, Martin Rutegård 30, Hanna Nyström 30, Nicholas J Wareham 31, Kay-Tee Khaw 32, Kathryn E Bradbury 33, Isabelle Romieu 1, Heinz Freisling 1, Faidra Stavropoulou 1, Marc J Gunter 34, Amanda J Cross 34, Elio Riboli 34, Mazda Jenab 35, W Robert Bruce 36
Affiliations
- PMID: 26404963
- PMCID: PMC6284787
- DOI: 10.1158/1055-9965.EPI-15-0422
The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk
So Yeon Kong et al. Cancer Epidemiol Biomarkers Prev. 2015 Dec.
Abstract
Background: A large proportion of colorectal cancers are thought to be associated with unhealthy dietary and lifestyle exposures, particularly energy excess, obesity, hyperinsulinemia, and hyperglycemia. It has been suggested that these processes stimulate the production of toxic reactive carbonyls from sugars such as glyceraldehyde. Glyceraldehyde contributes to the production of a group of compounds known as glyceraldehyde-derived advanced glycation end-products (glycer-AGEs), which may promote colorectal cancer through their proinflammatory and pro-oxidative properties. The objective of this study nested within a prospective cohort was to explore the association of circulating glycer-AGEs with risk of colorectal cancer.
Methods: A total of 1,055 colorectal cancer cases (colon n = 659; rectal n = 396) were matchced (1:1) to control subjects. Circulating glycer-AGEs were measured by a competitive ELISA. Multivariable conditional logistic regression models were used to calculate ORs and 95% confidence intervals (95% CI), adjusting for potential confounding factors, including smoking, alcohol, physical activity, body mass index, and diabetes status.
Results: Elevated glycer-AGEs levels were not associated with colorectal cancer risk (highest vs. lowest quartile, 1.10; 95% CI, 0.82-1.49). Subgroup analyses showed possible divergence by anatomical subsites (OR for colon cancer, 0.83; 95% CI, 0.57-1.22; OR for rectal cancer, 1.90; 95% CI, 1.14-3.19; Pheterogeneity = 0.14).
Conclusions: In this prospective study, circulating glycer-AGEs were not associated with risk of colon cancer, but showed a positive association with the risk of rectal cancer.
Impact: Further research is needed to clarify the role of toxic products of carbohydrate metabolism and energy excess in colorectal cancer development.
©2015 American Association for Cancer Research.
Conflict of interest statement
Conflict of interest:
The authors declare that they have no competing or conflict of interests.
Similar articles
- Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients.
Mao Z, Baker JR, Takeuchi M, Hyogo H, Tjønneland A, Eriksen AK, Severi G, Rothwell J, Laouali N, Katzke V, Kaaks R, Schulze MB, Palli D, Sieri S, de Magistris MS, Tumino R, Sacerdote C, Derksen JWG, Gram IT, Skeie G, Sandanger TM, Quirós JR, Crous-Bou M, Sánchez MJ, Amiano P, Colorado-Yohar SM, Guevara M, Harlid S, Johansson I, Perez-Cornago A, Freisling H, Gunter M, Weiderpass E, Heath AK, Aglago E, Jenab M, Fedirko V. Mao Z, et al. Int J Cancer. 2023 Jun 1;152(11):2257-2268. doi: 10.1002/ijc.34449. Epub 2023 Mar 20. Int J Cancer. 2023. PMID: 36715363 - Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer.
Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Jiao L, et al. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8. doi: 10.1158/1055-9965.EPI-11-0066. Epub 2011 Apr 28. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21527578 Free PMC article. - Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.
Aglago EK, Schalkwijk CG, Freisling H, Fedirko V, Hughes DJ, Jiao L, Dahm CC, Olsen A, Tjønneland A, Katzke V, Johnson T, Schulze MB, Aleksandrova K, Masala G, Sieri S, Simeon V, Tumino R, Macciotta A, Bueno-de-Mesquita B, Skeie G, Gram IT, Sandanger T, Jakszyn P, Sánchez MJ, Amiano P, Colorado-Yohar SM, Gurrea AB, Perez-Cornago A, Mayén AL, Weiderpass E, Gunter MJ, Heath AK, Jenab M. Aglago EK, et al. Carcinogenesis. 2021 May 28;42(5):705-713. doi: 10.1093/carcin/bgab026. Carcinogenesis. 2021. PMID: 33780524 Free PMC article. - Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M, Yamagishi S. Takeuchi M, et al. Curr Pharm Des. 2008;14(10):973-8. doi: 10.2174/138161208784139693. Curr Pharm Des. 2008. PMID: 18473848 Review. - Structures of Toxic Advanced Glycation End-Products Derived from Glyceraldehyde, A Sugar Metabolite.
Sakai-Sakasai A, Takeda K, Suzuki H, Takeuchi M. Sakai-Sakasai A, et al. Biomolecules. 2024 Feb 8;14(2):202. doi: 10.3390/biom14020202. Biomolecules. 2024. PMID: 38397439 Free PMC article. Review.
Cited by
- Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD.
Takeuchi M, Takino JI, Sakasai-Sakai A, Takata T, Tsutsumi M. Takeuchi M, et al. Nutrients. 2017 Jun 20;9(6):634. doi: 10.3390/nu9060634. Nutrients. 2017. PMID: 28632197 Free PMC article. Review. - Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development.
Azizian-Farsani F, Abedpoor N, Hasan Sheikhha M, Gure AO, Nasr-Esfahani MH, Ghaedi K. Azizian-Farsani F, et al. Front Oncol. 2020 Sep 29;10:552283. doi: 10.3389/fonc.2020.552283. eCollection 2020. Front Oncol. 2020. PMID: 33117687 Free PMC article. Review. - Effects of Toxic AGEs (TAGE) on Human Health.
Takeuchi M, Sakasai-Sakai A, Takata T, Takino JI, Koriyama Y. Takeuchi M, et al. Cells. 2022 Jul 12;11(14):2178. doi: 10.3390/cells11142178. Cells. 2022. PMID: 35883620 Free PMC article. Review. - Lysyl Oxidase and the Tumor Microenvironment.
Wang TH, Hsia SM, Shieh TM. Wang TH, et al. Int J Mol Sci. 2016 Dec 29;18(1):62. doi: 10.3390/ijms18010062. Int J Mol Sci. 2016. PMID: 28036074 Free PMC article. Review. - Advanced Glycation End-Products Acting as Immunomodulators for Chronic Inflammation, Inflammaging and Carcinogenesis in Patients with Diabetes and Immune-Related Diseases.
Shen CY, Lu CH, Cheng CF, Li KJ, Kuo YM, Wu CH, Liu CH, Hsieh SC, Tsai CY, Yu CL. Shen CY, et al. Biomedicines. 2024 Jul 31;12(8):1699. doi: 10.3390/biomedicines12081699. Biomedicines. 2024. PMID: 39200164 Free PMC article. Review.
References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69–90. - PubMed
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010;127:2893–917. - PubMed
- Colorectal Cancer 2011 Report: Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. World Cancer Research Fund / American Institute for Cancer Research; 2011.
- Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American journal of clinical nutrition. 2007;86:s836–42. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- WT_/Wellcome Trust/United Kingdom
- BHF_/British Heart Foundation/United Kingdom
- MC_UU_12015/1/MRC_/Medical Research Council/United Kingdom
- DH_/Department of Health/United Kingdom
- G0401527/MRC_/Medical Research Council/United Kingdom
- G1000143/MRC_/Medical Research Council/United Kingdom
- 16491/CRUK_/Cancer Research UK/United Kingdom
- 14136/CRUK_/Cancer Research UK/United Kingdom
- 001/WHO_/World Health Organization/International
- MC_U106179471/MRC_/Medical Research Council/United Kingdom